Clinical implication of Sox9 and activated Akt expression in pancreatic ductal adenocarcinoma
详细信息 查看全文
- 作者：Suhua Xia (1)
Zhenyu Feng (2)
Xiaowei Qi (3)
Yuan Yin (3)
Jianqiang Jin (3)
Yufeng Wu (4)
Haorong Wu (2)
Yizhong Feng (5)
Min Tao (1) (6) - 关键词：Pancreatic ductal adenocarcinoma ; Sox9 ; p ; Akt ; Prognosis
- 刊名：Medical Oncology
- 出版年：2015
- 出版时间：January 2015
- 年：2015
- 卷：32
- 期：1
- 全文大小：8,177 KB
- 参考文献：1. Pritchett J, Athwal V, Roberts N, Hanley NA, Hanley KP. Understanding the role of SOX9 in acquired diseases: lessons from development. Trends Mol Med. 2011;17(3):166-4. doi:10.1016/j.molmed.2010.12.001 . nal" href="http://dx.doi.org/10.1016/j.molmed.2010.12.001" target="_blank" title="It opens in new window">CrossRef
2. Wagner T, Wirth J, Meyer J, Zabel B, Held M, Zimmer J, et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell. 1994;79(6):1111-0. nal" href="http://dx.doi.org/10.1016/0092-8674(94)90041-8" target="_blank" title="It opens in new window">CrossRef
3. Kawaguchi Y. Sox9 and programming of liver and pancreatic progenitors. J Clin Investig. 2013;123(5):1881-. doi:10.1172/jci66022 . nal" href="http://dx.doi.org/10.1172/JCI66022" target="_blank" title="It opens in new window">CrossRef
4. Piper K, Ball SG, Keeling JW, Mansoor S, Wilson DI, Hanley NA. Novel SOX9 expression during human pancreas development correlates to abnormalities in Campomelic dysplasia. Mech Dev. 2002;116(1-):223-. nal" href="http://dx.doi.org/10.1016/S0925-4773(02)00145-4" target="_blank" title="It opens in new window">CrossRef
5. Furuyama K, Kawaguchi Y, Akiyama H, Horiguchi M, Kodama S, Kuhara T, et al. Continuous cell supply from a Sox9-expressing progenitor zone in adult liver, exocrine pancreas and intestine. Nat Genet. 2011;43(1):34-1. doi:10.1038/ng.722 . nal" href="http://dx.doi.org/10.1038/ng.722" target="_blank" title="It opens in new window">CrossRef
6. Seymour PA, Freude KK, Tran MN, Mayes EE, Jensen J, Kist R, et al. SOX9 is required for maintenance of the pancreatic progenitor cell pool. Proc Natl Acad Sci USA. 2007;104(6):1865-0. doi:10.1073/pnas.0609217104 . nal" href="http://dx.doi.org/10.1073/pnas.0609217104" target="_blank" title="It opens in new window">CrossRef
7. Matheu A, Collado M, Wise C, Manterola L, Cekaite L, Tye AJ, et al. Oncogenicity of the developmental transcription factor Sox9. Cancer Res. 2012;72(5):1301-5. doi:10.1158/0008-5472.can-11-3660 . nal" href="http://dx.doi.org/10.1158/0008-5472.CAN-11-3660" target="_blank" title="It opens in new window">CrossRef
8. Wang L, He S, Yuan J, Mao X, Cao Y, Zong J, et al. Oncogenic role of SOX9 expression in human malignant glioma. Med Oncol. 2012;29(5):3484-0. doi:10.1007/s12032-012-0267-z . nal" href="http://dx.doi.org/10.1007/s12032-012-0267-z" target="_blank" title="It opens in new window">CrossRef
9. Sun L, Mathews LA, Cabarcas SM, Zhang X, Yang A, Zhang Y, et al. Epigenetic regulation of SOX9 by the NF-kappaB signaling pathway in pancreatic cancer stem cells. Stem Cells. 2013;31(8):1454-6. doi:10.1002/stem.1394 . nal" href="http://dx.doi.org/10.1002/stem.1394" target="_blank" title="It opens in new window">CrossRef
10. Vivanco I, Sawyers CL. The phosphatidylinositol 3-Kinase AKT pathway in human cancer. Nat Rev Cancer. 2002;2(7):489-01. doi:10.1038/nrc839 . nal" href="http://dx.doi.org/10.1038/nrc839" target="_blank" title="It opens in new window">CrossRef
11. Kumar A, Rajendran V, Sethumadhavan R, Purohit R. AKT kinase pathway: a leading target in cancer research. Sci World J. 2013;2013:756134. doi:10.1155/2013/756134 .
12. Hollander MC, Blumenthal GM, Dennis PA. PTEN loss in the continuum of common cancers, rare syndromes and mouse models. Nat Rev Cancer. 2011;11(4):289-01. doi:10.1038/nrc3037 . nal" href="http://dx.doi.org/10.1038/nrc3037" target="_blank" title="It opens in new window">CrossRef
13. Baselga J, Swain SM. Novel anticancer targets: revisiting ERBB2 and discovering ERBB3. Nat Rev Cancer. 2009;9(7):463-5. doi:10.1038/nrc2656 . nal" href="http://dx.doi.org/10.1038/nrc2656" target="_blank" title="It opens in new window">CrossRef
14. Engelman JA. Targeting PI3K signalling in cancer: opportunities, challenges and limitations. Nat Rev Cancer. 2009;9(8):550-2. doi:10.1038/nrc2664 . nal" href="http://dx.doi.org/10.1038/nrc2664" target="_blank" title="It opens in new window">CrossRef
15. Chadha KS, Khoury T, Yu J, Black JD, Gibbs JF, Kuvshinoff BW, et al. Activated Akt and Erk expression and survival after surgery in pancreatic carcinoma. Ann Surg Oncol. 2006;13(7):933-. doi:Zhenyu Feng (2)
Xiaowei Qi (3)
Yuan Yin (3)
Jianqiang Jin (3)
Yufeng Wu (4)
Haorong Wu (2)
Yizhong Feng (5)
Min Tao (1) (6)
1. Department of Oncology, The First Affiliated Hospital of Soochow University, Suzhou, 215006, Jiangsu, People’s Republic of China
2. Department of General Surgery, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, Jiangsu, People’s Republic of China
3. Department of Pathology and Wuxi Oncology Institute, The Affiliated Hospital of Jiangnan University, Wuxi, 214062, Jiangsu, People’s Republic of China
4. Department of Internal Medicine, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, 450008, Henan, People’s Republic of China
5. Department of Pathology, The Second Affiliated Hospital of Soochow University, Suzhou, 215004, Jiangsu, People’s Republic of China
6. Jiangsu Institute of Clinical Immunology, Suzhou, 215006, Jiangsu, People’s Republic of China - ISSN：1559-131X
文摘
Pancreatic ductal adenocarcinoma (PDAC) is one of the most leading causes of cancer-related death. Cancer stem cell is responsible for tumor initiation, metastasis and relapse. Sox9 is a pancreatic stem cell marker. PI3K/PTEN/Akt/mTORC is an important signal for maintaining stem cells. The purpose of this study is to determine the expression pattern of Sox9 and p-Akt in human PDAC and its correlation with prognosis. Immunohistochemical analysis was used to explore the expression of Sox9 and p-Akt in 88 human PDAC patients. The Pearson’s test was used to compare the clinicopathological parameters between negative and positive expressors. The Pearson’s correlation analysis was used to explore the relationship between Sox9 and p-Akt expression. Kaplan–Meier’s method and Cox regression analysis were used to analyze patients-survival. The?results showed that?Sox9 and p-Akt overactivated in PDAC (p?=?0.011, p?=?0.008). Sox9-positive expression is?significantly associated with distant metastasis (p?=?0.046). p-Akt-positive expression is?significantly associated with distant metastasis (p?=?0.000), TNM stage (0.001) and PCNA expression (p?=?0.000). Sox9 expression is?positively correlated with p-Akt expression (r?=?0.314, p?=?0.003). In 54 patients with survival information, both Sox9- and p-Akt-positive expressions are?associated with unfavorable prognosis (p?=?0.002, p?=?0.000). Sox9 and p-Akt double-positive expressor showed much poorer prognosis (p?=?0.000). Cox regression analysis showed that?Sox9- or p-Akt-positive expression and LN metastasis were independent prognostic factors. This study provides the first evidence that Sox9 and p-Akt are both relevant to distant metastasis and proliferation. Our data suggest the potential of Sox9 and p-Akt as prognostic biomarkers for PDAC.